Stockscreener 앱 받기
1.01
0.97%
-0.02
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
Artelo Biosciences (NASDAQ:ARTL) Shares Down 11.2% – What’s Next? - Defense World
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Advances Novel Pain Therapy with Upcoming Data - GuruFocus
Artelo Biosciences (ARTL) Advances Cancer Therapy Pipeline - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Artelo Biosciences stock hits 52-week low at $0.91 - Investing.com
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025 - The Manila Times
New Data Reveals Artelo's FABP5 Inhibitor Could Transform Pain and Cancer Treatment - Stock Titan
Artelo Biosciences (ARTL) Projected to Post Earnings on Monday - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
HC Wainwright Has Pessimistic View of ARTL FY2025 Earnings - Defense World
Artelo Biosciences Reports 2024 Financial Results and Clinical Progress - TipRanks
Artelo Biosciences (NASDAQ:ARTL) Given Buy Rating at HC Wainwright - Defense World
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results - The Manila Times
ARTELO BIOSCIENCES, INC. SEC 10-K Report - TradingView
Can Artelo's Three Clinical Programs Overcome Its $9.8M Annual Loss? - StockTitan
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Increase in Short Interest - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Artelo Biosciences reports promising nonclinical CBD study - MSN
Analyzing Artelo Biosciences (NASDAQ:ARTL) & Rafael (NYSE:RFL) - Defense World
Artelo Biosciences Reports Positive ART12.11 Tablet Data Showing Improved Pharmacokinetics - Nasdaq
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - GlobeNewswire
Revolutionary CBD Tablet Formulation Achieves Breakthrough Pharmacokinetic Results vs Epidiolex - StockTitan
Artelo Biosciences to Present its New Data on ART12.11 - GlobeNewswire
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland - The Manila Times
Artelo's CBD Innovation Matches Epidiolex PerformanceGroundbreaking Study Revealed - StockTitan
Artelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium - Marketscreener.com
Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Drops By 42.2% - Defense World
Drug Designed to Treat Neuropathy Advances in Clinical Trials - Stony Brook University
Artelo Biosciences (NASDAQ:ARTL) Earns Buy Rating from D. Boral Capital - Defense World
Aemetis, Inc. (NASDAQ:AMTX) Holdings Trimmed by Jane Street Group LLC - Defense World
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - The Manila Times
Artelo Biosciences Completes First Phase 1 Cohort for Novel FABP5 Pain Treatment ART26.12 - StockTitan
EXCLUSIVE: Artelo Biosciences Concludes First Cohort Of Healthy Volunteers Of FABP Inhibitor Program - Benzinga
Artelo Biosciences Holds Annual Meeting; Directors Re-Elected and Independent Auditor Appointment Ratified - Defense World
Artelo Biosciences stock hits 52-week low at $0.97 By Investing.com - Investing.com Canada
Artelo Biosciences stock hits 52-week low at $0.97 - Investing.com
Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia - Yahoo Finance
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
California Biopharma Shows Promising Phase 1 Data - Streetwise Reports
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia - The Manila Times
Artelo's Cancer Drug Shows Breakthrough Results: 67% of Patients Reverse Weight Loss in Phase 1 Trial - StockTitan
Artelo Biosciences (ARTL) Stock Surges 5% Amid Strong Buy Ratings - GuruFocus.com
Artelo Biosciences (ARTL) Shares Drop Amidst Biotech Sector Move - GuruFocus.com
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
Artelo Biosciences to Present Key Drug Development Data at Major Cannabinoid Summit | ARTL Stock News - StockTitan
HC Wainwright Has Negative Outlook of ARTL FY2024 Earnings - Defense World
0.63%
자본화:
|
볼륨(24시간):